NCT00242840View on ClinicalTrials.gov

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Infection, Human Immunodeficiency Virus IHIV Infection
Interventions
DRUG

No intervention; Observational study

Trial Locations (7)

25125

GSK Investigational Site, Brescia

30308

GSK Investigational Site, Atlanta

30912

GSK Investigational Site, Augusta

32804

GSK Investigational Site, Orlando

33308

GSK Investigational Site, Fort Lauderdale

33614

GSK Investigational Site, Tampa

30308/30309

GSK Investigational Site, Atlanta

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY